Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | BLM | P54132 | 1/20 | 0.43 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9756796 | 1.00 | LMNA (0.59) | LMNABLMPTPN1MEN1CYP3A4 | |
| SCHEMBL9717073 | 1.00 | LMNA (0.59) | LMNABLMPTPN1MEN1CYP3A4 | |
| Water SCHEMBL15312410 | 0.98 | LMNA (0.56) | LMNABLMPTPN1MEN1CYP3A4 | |
| SCHEMBL10535505 | 0.91 | LMNA (0.59) | LMNABLMPTPN1MEN1CYP3A4 | |
| SCHEMBL10535502 | 0.91 | LMNA (0.59) | LMNABLMPTPN1MEN1CYP3A4 | |
| SCHEMBL11455553 | 0.83 | LMNA (0.62) | LMNABLMPTPN1MEN1CYP3A4 | |
| SCHEMBL11463913 | 0.83 | LMNA (0.62) | LMNABLMPTPN1MEN1CYP3A4 | |
| SCHEMBL669828 | 0.79 | — | — | |
| SCHEMBL336892 | 0.79 | — | — | |
| SCHEMBL20928 | 0.79 | LMNA (0.93) | LMNABLMPTPN1MEN1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025242747-A1 | MULTI -COMPONENT FORMULATIONS OF ORGANOMETALLIC REAGENTS | MERCK PATENT GMBH (DE) | 2025-11-27 | — | — | WO | claimed |
| CN-118769745-A | Cold and hot tearing type transfer printing film and preparation method thereof | 江苏新光镭射包装材料股份有限公司 | 2024-10-15 | — | — | CN | claimed |
| WO-2025242747-A1 | MULTI -COMPONENT FORMULATIONS OF ORGANOMETALLIC REAGENTS | MERCK PATENT GMBH (DE) | 2025-11-27 | — | — | WO | disclosed |
| US-20250312287-A1 | LIPID NANOPARTICLES COMPRISING AN IMIDAZOLIUM-BASED CATIONIC LIPID | POLYPLUS TRANSFECTION (FR) | 2025-10-09 | — | — | US | disclosed |
| EP-4551199-A1 | LIPID NANOPARTICLES COMPRISING AN IMIDAZOLIUM-BASED CATIONIC LIPID | PolyPlus Transfection (FR) | 2025-05-14 | — | — | EP | disclosed |
| US-20250074866-A1 | MODIFIED AMINE LIPIDS | INTELLIA THERAPEUTICS, INC. | 2025-03-06 | — | — | US | disclosed |
| CN-119486721-A | Lipid nanoparticles comprising imidazolium-based cationic lipids | 宝利普拉斯生物转染公司 | 2025-02-18 | — | — | CN | disclosed |
| CN-119285480-A | Modified amine lipids | 英特利亚治疗股份有限公司 | 2025-01-10 | — | — | CN | disclosed |
| CN-118769745-A | Cold and hot tearing type transfer printing film and preparation method thereof | 江苏新光镭射包装材料股份有限公司 | 2024-10-15 | — | — | CN | disclosed |
| US-12077483-B2 | Modified amine lipids | INTELLIA THERAPEUTICS, INC. (US) | 2024-09-03 | — | — | US | disclosed |
| WO-2024008967-A1 | LIPID NANOPARTICLES COMPRISING AN IMIDAZOLIUM-BASED CATIONIC LIPID | POLYPLUS TRANSFECTION (FR) | 2024-01-11 | — | — | WO | disclosed |
| US-20120205596-A1 | MACROMOLECULAR COMPOUND | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-08-16 | — | — | US | disclosed |
| US-20120205641-A1 | PHOTOVOLTAIC CELL | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-08-16 | — | — | US | disclosed |
| US-20120205644-A1 | PHOTOVOLTAIC CELL | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-08-16 | — | — | US | disclosed |
| EP-0414106-B1 | Process for the preparation of terpenes | EISAI CO LTD (JP) | 1996-03-27 | — | — | EP | disclosed |
| EP-0180399-B1 | ANTI-TUMOR 4-HYDROXY-2-CYCLOPENTENONES | TEIJIN LIMITED (JP) | 1992-05-20 | — | — | EP | disclosed |
| US-5073659-A | Alkylation, Grignard reagent, zinc chloride catalyst and coppe r compound | EISAI CO., LTD. (JP) | 1991-12-17 | — | — | US | disclosed |
| EP-0414106-A2 | Process for the preparation of terpenes | Eisai Co., Ltd. (JP) | 1991-02-27 | — | — | EP | disclosed |
| US-4711895-A | 4-hydroxy-2-cyclopentenone, process for production thereof, pharmaceutical composition comprising it | TEIJIN LIMITED (JP) | 1987-12-08 | — | — | US | disclosed |
| EP-0180399-A2 | Anti-tumor 4-Hydroxy-2-cyclopentenones | TEIJIN LIMITED (JP) | 1986-05-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250312287-A1 | LIPID NANOPARTICLES COMPRISING AN IMIDAZOLIUM-BASED CATIONIC LIPID | NPC1L1, CETP, LNPK | LMNA 194/4885BLM 4467/4885PTPN1 4196/4885 |
| US-12077483-B2 | Modified amine lipids | PHOSPHO1, SGMS1, SGMS2 | LMNA 1381/4885BLM 1522/4885PTPN1 3075/4885 |
| US-20250074866-A1 | MODIFIED AMINE LIPIDS | PHOSPHO1, SGMS1, SGMS2 | LMNA 1381/4885BLM 1522/4885PTPN1 3075/4885 |
| US-20120205596-A1 | MACROMOLECULAR COMPOUND | EXOSC4, TRPC6, MRPS22 | LMNA 3835/4885BLM 567/4885PTPN1 553/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.